Denali Therapeutics Inc.
US ˙ NasdaqGS ˙ US24823R1059

SecurityDNLI / Denali Therapeutics Inc.
InstitutionAxa S.a.
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Axa S.a. closes position in DNLI / Denali Therapeutics Inc.

On November 14, 2025 - Axa S.a. filed a 13F-HR form disclosing ownership of 0 shares of Denali Therapeutics Inc. (US:DNLI) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 14, 2025 disclosing 293,853 shares of Denali Therapeutics Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-11-14 2025-09-30 13F DENALI THERAPEUTICS COM 24823R105 0 -100.00 0
2025-08-14 2025-06-30 13F DENALI THERAPEUTICS COM 24823R105 293,853 472 0.16 4,111 3.08 0.0082
2025-05-15 2025-03-31 13F DENALI THERAPEUTICS COM 24823R105 293,381 -374 -0.13 3,989 -33.38 0.0131
2025-02-14 2024-12-31 13F DENALI THERAPEUTICS COM 24823R105 293,755 -51,128 -14.82 5,987 -40.41 0.0182
2024-11-14 2024-09-30 13F DENALI THERAPEUTICS COM 24823R105 344,883 98 0.03 10,046 25.50 0.0297
2025-02-25 2024-06-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 344,785 -16,023 -4.44 8,006 8.13 0.0238
2024-08-14 2024-06-30 13F DENALI THERAPEUTICS COM 24823R105 344,785 -16,023 8,006 0.0238
2024-05-15 2024-03-31 13F DENALI THERAPEUTICS COM 24823R105 360,808 213 0.06 7,404 -4.33 0.0222
2024-07-16 2023-12-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 360,595 6,066 1.71 7,738 5.81 0.0250
2024-02-14 2023-12-31 13F DENALI THERAPEUTICS COM 24823R105 360,595 6,066 7,738 0.0152
2023-11-14 2023-09-30 13F DENALI THERAPEUTICS COM 24823R105 354,529 -3,853 -1.08 7,314 -30.85 0.0257
2023-08-14 2023-06-30 13F DENALI THERAPEUTICS COM 24823R105 358,382 69,140 23.90 10,576 58.69 0.0351
2023-05-15 2023-03-31 13F DENALI THERAPEUTICS COM 24823R105 289,242 -678 -0.23 6,664 -17.34 0.0229
2023-02-14 2022-12-31 13F DENALI THERAPEUTICS COM 24823R105 289,920 41,148 16.54 8,063 5.61 0.0291
2023-02-14 2022-09-30 13F/A-1 Denali Therapeutics COM 24823R105 248,772 1,081 0.44 7,635 4.73 0.0300
2022-11-14 2022-09-30 13F Denali Therapeutics COM 24823R105 248,772 1,081 7,635 0.0300
2023-02-14 2022-06-30 13F/A-1 Denali Therapeutics COM 24823R105 247,691 47,123 23.49 7,290 12.97 0.0270
2022-08-15 2022-06-30 13F Denali Therapeutics COM 24823R105 247,691 47,123 7,290 0.0270
2023-02-14 2022-03-31 13F/A-1 Denali Therapeutics COM 24823R105 200,568 -19,498 -8.86 6,452 -34.26 0.0183
2022-05-13 2022-03-31 13F Denali Therapeutics COM 24823R105 200,568 -19,498 6,452 0.0183
2022-02-14 2021-12-31 13F Denali Therapeutics COM 24823R105 220,066 18,486 9.17 9,815 -3.49 0.0251
2021-11-15 2021-09-30 13F Denali Therapeutics COM 24823R105 201,580 18,880 10.33 10,170 -29.03 0.0285
2021-08-13 2021-06-30 13F/A-1 Denali Therapeutics COM 24823R105 182,700 5,722 3.23 14,331 41.82 0.0404
2021-08-13 2021-06-30 13F Denali Therapeutics COM 24823R105 182,700 5,722 14,331 0.0242
2021-05-14 2021-03-31 13F Denali Therapeutics COM 24823R105 176,978 18,788 11.88 10,105 -23.74 0.0308
2021-02-12 2020-12-31 13F Denali Therapeutics COM 24823R105 158,190 -64,881 -29.09 13,250 65.77 0.0416
2021-02-11 2020-09-30 13F/A-1 Denali Therapeutics COM 24823R105 223,071 -2,119 -0.94 7,993 46.80 0.0289
2020-11-13 2020-09-30 13F Denali Therapeutics COM 24823R105 223,071 -2,119 7,993 15,955.2966
2021-02-12 2020-06-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 225,190 37,228 19.81 5,445 65.45 0.0215
2020-08-14 2020-06-30 13F DENALI THERAPEUTICS COM 24823R105 225,190 37,228 5,445 21,473.1521
2021-02-12 2020-03-31 13F/A-2 DENALI THERAPEUTICS COM 24823R105 187,962 187,962 3,291 0.0164
2020-06-15 2020-03-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 187,962 0 3,291 0.0165
2020-05-15 2020-03-31 13F DENALI THERAPEUTICS COM 24823R105 187,962 3,291 0.0165
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.